Mark Meadows Claims Trump Lied To Voters About 2020 Election, Do You Agree?

By

Sanders Opposes Biden’s Nominee for NIH Director Position

Senator Bernie Sanders, who chairs the Senate Committee on Health, Education, Labor and Pensions (HELP), has publicly announced that he will not be supporting Monica Bertagnolli, President Biden’s choice for the director of the National Institutes of Health (NIH). His announcement comes just ahead of a crucial meeting by the HELP committee, set to evaluate Bertagnolli’s candidacy among others for different governmental roles.

While acknowledging Bertagnolli’s qualifications and personal attributes, Sanders expressed deep reservations about her willingness to challenge big pharmaceutical companies and usher in much-needed reforms at NIH. He stated that he remains unconvinced that Bertagnolli would be a strong advocate against the pharmaceutical industry’s influence, something he views as critical for the role.

Earlier, Sanders had delayed the confirmation proceedings for Bertagnolli, insisting that he would only move forward once the Biden administration outlined concrete plans for reducing the soaring costs of prescription medications. Although he eventually agreed to let the confirmation hearing proceed, following some assurances from the White House on the matter, he still remains skeptical about the nominee.

Lawrence A. Tabak has been serving as the interim director of NIH since the departure of its former director, Francis Collins, in December 2021. During the preliminary hearing, Sanders emphasized his criteria for a suitable NIH director: someone willing to tackle pharmaceutical greed and actively work to bring down exorbitant drug prices.

Sanders queried Bertagnolli on her stand regarding the “reasonable pricing clause,” a policy from the late ’80s and ’90s, which mandated that drugs produced through public-private partnerships have a pricing model that is fair and justifies the public investment. This policy was later discarded in 1995, as it was perceived to deter potential collaborations.

In response, Bertagnolli acknowledged the need for fair pricing but stopped short of providing a detailed plan. She pledged to strive for research benefits that are both accessible and affordable for all Americans but failed to offer any specific strategies for achieving this aim. Given these factors, Sanders has decided to vote against her confirmation and described his choice as a “vote of conscience.”